Skip to content

Treatment-specific changes in decentering following mindfulness-based cognitive therapy versus antidepressant medication or placebo for prevention of depressive relapse.

Peter Bieling, Lance L. Hawley, Richard T. Bloch, Kathleen Corcoran, Robert D. Levitan, L. Trevor Young, Glenda Macqueen, Zindel V. Segal

Journal of Consulting and Clinical Psychology March 12, 2012 DOI: 10.1037/a0027483 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 84
Population Patients with a history of depression at risk of relapse
Interventions Mindfulness-based cognitive therapy Antidepressant medication Placebo
Duration 6-8 months of antidepressant treatment, then 18-month maintenance phase
Topics Anxiety Meditation
Keywords Rumination Mindfulness-based cognitive therapy Relapse prevention Randomized controlled trial Clinical psychology Placebo Psychotherapist Rating scale Curiosity Cognition Alternative medicine Developmental psychology
Citations 239
Post-publication review 1 comment on PubPeer (opens in new tab) · last active September 2016
Key findings Only patients receiving MBCT showed significant increases in decentering and wider experiences, and these changes predicted lower depression scores at 6-month follow-up.

Abstract

Objective: To examine whether metacognitive psychological skills, acquired in mindfulness-based cognitive therapy (MBCT), are also present in patients receiving medication treatments for prevention of depressive relapse and whether these skills mediate MBCT's effectiveness.

Method: This study, embedded within a randomized efficacy trial of MBCT, was the first to examine changes in mindfulness and decentering during 6-8 months of antidepressant treatment and then during an 18-month maintenance phase in which patients discontinued medication and received MBCT, continued on antidepressants, or were switched to a placebo. In total, 84 patients (mean age = 44 years, 58% female) were randomized to 1 of these 3 prevention conditions. In addition to symptom variables, changes in mindfulness, rumination, and decentering were assessed during the phases of the study.

Results: Pharmacological treatment of acute depression was associated with reductions in scores for rumination and increased wider experiences. During the maintenance phase, only patients receiving MBCT showed significant increases in the ability to monitor and observe thoughts and feelings as measured by the Wider Experiences (p < .01) and Decentering (p < .01) subscales of the Experiences Questionnaire and by the Toronto Mindfulness Scale. In addition, changes in Wider Experiences (p < .05) and Curiosity (p < .01) predicted lower Hamilton Rating Scale for Depression scores at 6-month follow-up.

Conclusions: An increased capacity for decentering and curiosity may be fostered during MBCT and may underlie its effectiveness. With practice, patients can learn to counter habitual avoidance tendencies and to regulate dysphoric affect in ways that support recovery.

Explore topics